Mitochondrial function, cellular energy, oxidative stress, anti-aging
SS-31 (Elamipretide)
A mitochondria-targeting peptide studied for cellular energy, ATP production, muscle function, oxidative stress, cardiovascular health, mitochondrial disease, and age-related mitochondrial decline.
Administration Reference
Subcutaneous
Source / Evidence Context
Mixed sources
Dose Information
1–10 mg daily, with 2–5 mg/day commonly discussed
Frequency
3–5 days per week
Duration / Cycle
6–12 weeks
Off-Cycle
Wide range; 6–8 weeks to 6 months
Timing
Morning or pre-exercise
Storage Guidance
Refrigerate after reconstitution and use within approximately 30 days, Freeze for lyophilized powder form
Supplies
Affiliate disclosure: We may earn a commission if you purchase through these links.
Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.
Syringes & transfer supplies
EasyTouch U-100 Insulin Syringes (31G 0.5cc 5/16″) – 100ct.U-100 Insulin Syringes (31G 0.5cc 5/16") – 100ctInsulin syringes – Polybag, 50 Unit Capacity, 5/16” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →
Exlavges 100 Pack Disposable 3ml/cc Lab Syringes23Ga 1 Inch Needle Luer LockIndividually Sealed PackedView at Amazon →
Protective supplies & disposal
MED PRIDE Sterile Alcohol Prep Pads1 BOX OF 200INDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 1 BOX OF 200, MEDIUM SIZE PREP PADSView at AMAZON →
Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →
Square Sharps Container, 2 QuartQTY 1View at AMAZON →
Commonly Reported Uses
Mitochondrial support; cellular energy and ATP production; fatigue and exercise-tolerance research; muscle performance and recovery; cardiovascular and cardiac-energy research; age-related mitochondrial decline; oxidative-stress reduction; neurological and kidney research. Its approved medical use is improvement of muscle strength in Barth syndrome.
Commonly Reported Indicators
Community reports commonly focus on improved daytime energy, stamina, exercise tolerance, recovery, reduced perceived fatigue, and clearer cognition. Research endpoints have included mitochondrial ATP production, 6-minute walk distance, fatigue scores, knee-extensor strength, cardiac function, and muscle performance.
Mechanism Overview
SS-31 concentrates at the inner mitochondrial membrane and interacts with cardiolipin, helping stabilize membrane structure and mitochondrial protein function. Research indicates improved electron transport, ATP production, ADP transport, oxidative phosphorylation efficiency, and reduced excess mitochondrial oxidative stress.
Safety
Safety Considerations
Elamipretide now has considerably more human safety information than most research peptides. In the Barth syndrome clinical program, injection-site reactions were the dominant adverse effect. Serious hypersensitivity reactions have also occurred. Severe renal impairment requires dose reduction under the approved prescribing information.
Reported Adverse Effects
Injection-site redness, pain, itching, induration, bruising and urticaria are the most consistently documented effects. Hypersensitivity can include rash, papular lesions, eczematous dermatitis, cough, and rarely serious allergic reactions. Mild nausea and headache have also occurred in earlier clinical studies.
Contraindications & Cautions
Serious hypersensitivity to elamipretide or formulation ingredients is a formal contraindication. Additional considerations include severe renal impairment, pregnancy or breastfeeding, and use of benzyl-alcohol-containing approved formulations in neonates. Research-grade preparations add separate concerns involving sterility, concentration, and product quality.
Cancer Considerations
Editorial evidence assessment, not a validated risk score or clearance for use. Unknown risk does not mean low risk; these notes do not establish safety during active cancer or remission.
Cancer Concern Assessment
Low theoretical concern
Basis for Concern
Elamipretide does not primarily act through GH/IGF-1, VEGF, or other classic proliferative pathways associated with higher theoretical cancer concern. However, mitochondrial metabolism influences tumor-cell survival and proliferation, so a theoretical interaction cannot be excluded. Formal carcinogenicity studies of elamipretide have not been conducted; standard genotoxicity tests were negative.
Active Cancer
Insufficient evidence
No clinical evidence currently demonstrates that elamipretide promotes tumor growth, but controlled studies specifically evaluating its use during active malignancy are lacking. Its mitochondrial mechanism warrants individual consideration rather than assuming either harm or safety.
Prior Cancer / Remission
Insufficient evidence
No evidence-based remission interval has been established. Elamipretide is not known to stimulate a major growth-factor pathway, and available genotoxicity testing is negative, but recurrence-specific human data are unavailable.
Status
Regulatory Status
Prescription elamipretide is an FDA-approved medication for Barth syndrome. SS-31 sold separately by research suppliers should not be considered equivalent to FORZINITY in formulation, quality controls, concentration, or regulatory status. Other proposed uses—including longevity, general mitochondrial optimization, cardiovascular support, and exercise enhancement—remain outside the approved indication.
Development / Research Status
Approved medication
Market Classification
Varies by jurisdiction or formulation
Status Notes
Prescription elamipretide is an FDA-approved medication for Barth syndrome. SS-31 sold separately by research suppliers should not be considered equivalent to FORZINITY in formulation, quality controls, concentration, or regulatory status. Other proposed uses—including longevity, general mitochondrial optimization, cardiovascular support, and exercise enhancement—remain outside the approved indication.
Research & Evidence
Evidence Level
Approved clinical use
Research Last Reviewed
2026-09-06
Research Overview
SS-31 has progressed from extensive mitochondrial and animal research into multiple randomized human trials and an FDA-approved therapy. Human studies include Barth syndrome, primary mitochondrial myopathy, aging muscle, and heart failure. Results are mixed by indication: several trials showed biological or secondary-endpoint improvements despite missing their primary endpoints, while long-term Barth syndrome data ultimately supported accelerated approval.
Human Research
In Barth syndrome, the randomized TAZPOWER phase initially failed to show superiority on its two primary endpoints, but open-label follow-up demonstrated progressive improvements in functional measures. At 168 weeks, eight continuing participants showed sustained improvement in 6-minute walk distance, fatigue measures, cardiac parameters, and cardiolipin biomarkers. These data contributed to the later accelerated approval based on improvement in knee-extensor muscle strength.
In primary mitochondrial myopathy, MMPOWER-2 enrolled 30 patients receiving 40 mg/day for four weeks. The 6-minute walk primary endpoint did not reach statistical significance, although several fatigue and patient-reported measures improved. The larger Phase 3 MMPOWER-3 trial subsequently tested 40 mg/day for 24 weeks but did not meet its primary efficacy endpoints across the overall population.
A randomized study in 39 adults aged 60–85 with impaired mitochondrial function found that a single elamipretide infusion increased skeletal-muscle mitochondrial ATP-production capacity shortly after treatment, although it did not significantly improve measured muscle fatigue resistance.
A randomized heart-failure study also evaluated elamipretide and demonstrated acceptable short-term tolerability while providing human evidence that mitochondrial-targeted therapy can influence cardiac structural and energetic endpoints.
Animal Research
Aged-mouse studies show some of the strongest longevity-related signals. SS-31 rapidly restored mitochondrial ATP production and oxidative-phosphorylation coupling, reduced mitochondrial oxidative stress, improved skeletal-muscle fatigue resistance, and increased endurance. Longer treatment has also improved aged cardiac and skeletal-muscle function without measurably reversing epigenetic or transcriptomic age itself.
Research has additionally examined SS-31 in models involving cardiac dysfunction, ischemia-reperfusion injury, kidney injury, neurodegeneration, traumatic brain injury, spinal-cord injury, and other disorders involving mitochondrial dysfunction. A 2026 spinal-cord-injury study reported preserved mitochondrial bioenergetics and improved neural recovery in a preclinical model.
In Vitro Research
Laboratory research shows that SS-31 interacts directly with cardiolipin-containing mitochondrial membranes and multiple mitochondrial proteins. It improves ADP sensitivity through the adenine nucleotide translocator, influences ATP synthase and electron-transport proteins, reduces oxidative damage, and improves mitochondrial membrane organization and bioenergetics.
References
U.S. Food and Drug Administration. FORZINITY (elamipretide) Injection Prescribing Information. Initial U.S. Approval 2025.
U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. September 19, 2025.
Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021;23:471-478. PMID 33077895. DOI 10.1038/s41436-020-01006-8.
Thompson WR, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138. PMID 38602181. DOI 10.1016/j.gim.2024.101138.
Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90:e1212-e1221. PMID 29500292.
Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle. 2020;11:909-918. PMID 32096613. DOI 10.1002/jcsm.12559.
Karaa A, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101:e238-e252. PMID 37268435. DOI 10.1212/WNL.0000000000207402.
Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021;16:e0253849. PMID 34264994. DOI 10.1371/journal.pone.0253849.
Daubert MA, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017. PMID 29217757. DOI 10.1161/CIRCHEARTFAILURE.117.004389.
Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013. PMID 23692570. DOI 10.1111/acel.12102.
Campbell MD, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281. PMID 30597195.
Pharaoh G, et al. The mitochondrially targeted peptide elamipretide improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator. Geroscience. 2023;45:3529-3548. PMID 37462785. DOI 10.1007/s11357-023-00861-y.
Mitchell W, et al. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. 2025;24:e70026. PMID 40080911. DOI 10.1111/acel.70026.
Mitchell W, et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. J Biol Chem. 2020;295:7452-7469. PMID 32273339. DOI 10.1074/jbc.RA119.012094.
Chavez JD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci USA. 2020;117:15363-15373. PMID 32554501. DOI 10.1073/pnas.2002250117.
Song Z, et al. Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury. Neurochem Int. 2026;197:106171. PMID 42082001. DOI 10.1016/j.neuint.2026.106171.
Vyas S, Zaganjor E, Haigis MC. Mitochondria and Cancer. Mol Cell. 2016;61:667-676. PMID 26942671. DOI 10.1016/j.molcel.2016.02.011.
Peptide Protocol Wiki. SS-31 Dosing Protocols and Administration. Updated 2026.
PeptideDosage.org. SS-31 Dosage Chart, Schedule & Reconstitution Protocol. Reviewed May 21, 2026.